Nano cap Prosensa Holding N.V. (RNA) is up 28% premarket on light volume apparently riding on Sarepta's coattails.
Prosensa has its own product candidate, drisapersin, for Duchenne Muscular Dystrophy. A Phase 3 clinical trial failed, however, to meet its primary endpoint of demonstrating a statistically significant or clinically meaningful treatment difference compared to placebo. The drug also failed to meet the majority of its secondary endpoints.
Retail investors should tread carefully here.